Cargando…
CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs)...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413600/ https://www.ncbi.nlm.nih.gov/pubmed/28401346 http://dx.doi.org/10.1007/s13238-017-0397-3 |
_version_ | 1783233212110077952 |
---|---|
author | Wang, Lixia Yi, Fei Fu, Lina Yang, Jiping Wang, Si Wang, Zhaoxia Suzuki, Keiichiro Sun, Liang Xu, Xiuling Yu, Yang Qiao, Jie Belmonte, Juan Carlos Izpisua Yang, Ze Yuan, Yun Qu, Jing Liu, Guang-Hui |
author_facet | Wang, Lixia Yi, Fei Fu, Lina Yang, Jiping Wang, Si Wang, Zhaoxia Suzuki, Keiichiro Sun, Liang Xu, Xiuling Yu, Yang Qiao, Jie Belmonte, Juan Carlos Izpisua Yang, Ze Yuan, Yun Qu, Jing Liu, Guang-Hui |
author_sort | Wang, Lixia |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 (+/A272C) and FUS (+/G1566A) mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 (+/A272C) and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-017-0397-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5413600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Higher Education Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54136002017-05-18 CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs Wang, Lixia Yi, Fei Fu, Lina Yang, Jiping Wang, Si Wang, Zhaoxia Suzuki, Keiichiro Sun, Liang Xu, Xiuling Yu, Yang Qiao, Jie Belmonte, Juan Carlos Izpisua Yang, Ze Yuan, Yun Qu, Jing Liu, Guang-Hui Protein Cell Research Article Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 (+/A272C) and FUS (+/G1566A) mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 (+/A272C) and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-017-0397-3) contains supplementary material, which is available to authorized users. Higher Education Press 2017-04-11 2017-05 /pmc/articles/PMC5413600/ /pubmed/28401346 http://dx.doi.org/10.1007/s13238-017-0397-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article Wang, Lixia Yi, Fei Fu, Lina Yang, Jiping Wang, Si Wang, Zhaoxia Suzuki, Keiichiro Sun, Liang Xu, Xiuling Yu, Yang Qiao, Jie Belmonte, Juan Carlos Izpisua Yang, Ze Yuan, Yun Qu, Jing Liu, Guang-Hui CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title_full | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title_fullStr | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title_full_unstemmed | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title_short | CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs |
title_sort | crispr/cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient ipscs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413600/ https://www.ncbi.nlm.nih.gov/pubmed/28401346 http://dx.doi.org/10.1007/s13238-017-0397-3 |
work_keys_str_mv | AT wanglixia crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT yifei crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT fulina crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT yangjiping crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT wangsi crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT wangzhaoxia crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT suzukikeiichiro crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT sunliang crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT xuxiuling crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT yuyang crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT qiaojie crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT belmontejuancarlosizpisua crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT yangze crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT yuanyun crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT qujing crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs AT liuguanghui crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs |